Bodenstedt Matthias 4

What Happened
Matthias Bodenstedt, MoonLake Immunotherapeutics' (MLTX) Chief Financial Officer, sold 2,426 shares in an open-market disposition on April 14, 2026 for a weighted average price of $19.56 per share, generating proceeds of approximately $47,453. The sale was executed under a Rule 10b5-1 trading plan adopted December 10, 2025, indicating it was a preplanned transaction rather than a spontaneous trade.

Key Details

• Transaction date: 2026-04-14; filing date (Form 4): 2026-04-16 (filed two days after the trade, generally within the standard two-business-day window).
• Shares sold: 2,426; weighted average price: $19.56; total proceeds ≈ $47,453.
• Price range: trades occurred at prices between $19.500 and $19.625 (weighted average reported). Per the filing, the reporting person will provide a breakdown of the number of shares sold at each price upon SEC/issuer/stockholder request.
• Shares owned after the transaction: not disclosed in the provided filing excerpt.
• Footnote: Sale executed pursuant to a Rule 10b5-1 plan (adopted 2025-12-10).

Context
Sales under 10b5-1 plans are prearranged and are commonly used by insiders to systematically sell shares; they do not necessarily indicate a change in the insider’s view of the company. For retail investors, purchases by insiders can be more informative than routine, preplanned sales. This filing appears to be routine and timely; no additional derivative exercises, gifts, or tax-withholding events were reported in the supplied excerpt.